[FLDM] Fluidigm Corporation


Type of security: Stock

Sector: Capital Goods

Industry: Biotechnology: Laboratory Analytical Instruments

Market Capitalization: 282.85 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 7.48 Change: 0.29 (4.03%)
Ext. hours: Change: 0 (0%)

chart FLDM

Refresh chart

Strongest Trends Summary For FLDM

FLDM is in the medium-term up 69% above S&P in 1 year. In the long-term up 80% in 2 years and down -80% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Fluidigm Corporation develops, manufactures, and sells microfluidic systems worldwide. It offers BioMark HD System that performs high-throughput and single-cell targeted gene expression analysis, single nucleotide polymorphism (SNP) genotyping, and digital polymerase chain reaction (PCR) using Fluidigm DELTAgene and SNPtype assays, other chemistries, and Fluidigm Dynamic Array and Digital Array integrated fluidic circuits (IFCs). The company also provides C1 Single-Cell Auto Prep System, which enables the isolation, processing, and profiling of individual cells for genomic analysis for applications comprising single-cell targeted gene expression, single-cell micro ribonucleic acid (RNA) analysis, single-cell messenger RNA analysis, and single-cell targeted DNA sequencing using the company?s C1 Single-Cell Auto Prep Array IFCs and C1 reagent kit. In addition, it offers EP1 System, which performs SNP genotyping using Fluidigm SNPtype assays or TagMan assays, as well as end-point digital PCR using TaqMan assays,

Fundamental Ratios
Shares Outstanding29.01 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -3.18% Sales Growth - Q/Q-20.19% P/E
P/E To EPS Growth P/S2.41 P/BV1.99 Price/Cash Per Share2.43
Price/Free Cash Flow-9.42 ROA-13.5% ROE-37.45% ROI-15.7%
Current Ratio6.23 Quick Ratio5.53 Long Term Debt/Equity1.5 Debt Ratio0.17
Gross Margin61.87% Operating Margin-41.94% Net Profit Margin-45.42% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities3.73 M Cash From Investing Activities10.07 M Cash From Operating Activities-9.8 M Gross Profit16.08 M
Net Profit-15.93 M Operating Profit-14 M Total Assets395.03 M Total Current Assets155.23 M
Total Current Liabilities24.9 M Total Debt195.51 M Total Liabilities252.58 M Total Revenue26.73 M
Technical Data
High 52 week8.35 Low 52 week4.86 Last close7.71 Last change-1.66%
RSI39.45 Average true range0.52 Beta1.2 Volume281.03 K
Simple moving average 20 days-3.51% Simple moving average 50 days-0.66% Simple moving average 200 days13.88%
Performance Data
Performance Week0.78% Performance Month-5.98% Performance Quart-7% Performance Half39.67%
Performance Year23.16% Performance Year-to-date30.9% Volatility daily2.32% Volatility weekly5.19%
Volatility monthly10.64% Volatility yearly36.87% Relative Volume318.24% Average Volume352.89 K
New High New Low


2019-03-18 17:48:34 | Fluidigm Corp FLDM Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-03-15 08:51:12 | Fluidigm FLDM in Focus: Stock Moves 8% Higher

2019-03-14 11:53:00 | Here's Why Fluidigm Rose as Much as 13.4% Today

2019-03-12 09:54:00 | Fluidigm Is Emerging From a Large Base Pattern, So Go Long

2019-03-08 07:47:00 | 3 Top Stocks Under $20

2019-03-05 08:30:00 | Colin McCracken Joins Fluidigm as Chief Commercial Officer

2019-02-22 17:30:00 | Fluidigm to Participate in Upcoming Investor Conferences

2019-02-19 14:00:00 | 3 Top Stocks That Aren't on Wall Street's Radar

2019-02-19 08:00:00 | Detailed Research: Economic Perspectives on Exxon Mobil, Loxo Oncology, Fluidigm, LHC Group, Ebix, and Omega Flex — What Drives Growth in Today's Competitive Landscape

2019-02-12 19:00:00 | Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-02-12 14:23:25 | Fluidigm Corporation NASDAQ:FLDM: Is It A Good Long Term Opportunity?

2019-02-11 17:03:00 | The 1 Stock I'd Buy Right Now

2019-02-08 18:45:13 | Edited Transcript of FLDM earnings conference call or presentation 7-Feb-19 10:00pm GMT

2019-02-08 15:55:00 | Here's Why Fluidigm Rose as Much as 14.2% Today

2019-02-07 20:09:42 | Fluidigm Corp FLDM Q4 2018 Earnings Conference Call Transcript

2019-02-07 18:50:11 | Fluidigm FLDM Reports Q4 Loss, Tops Revenue Estimates

2019-02-07 17:57:36 | Fluidigm: 4Q Earnings Snapshot

2019-02-07 16:05:00 | Fluidigm Announces Fourth Quarter and Full Year 2018 Financial Results

2019-02-07 09:00:00 | Fluidigm Announces Co-Marketing Agreement with Indica Labs to Offer Platform for Imaging Mass Cytometry Data Analysis to Aid Novel Digital Pathology Investigations

2019-02-07 08:30:00 | Fluidigm Announces Participation in Life Science/Pharma and Academic Consortium to Study T Cell-Driven Immune-Mediated Inflammatory Diseases

2019-01-31 08:30:00 | Fluidigm Introduces REAP-Seq for Multi-Omic Single-Cell Analysis on the C1

2019-01-24 07:55:00 | Consolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics — Fundamental Analysis, Key Performance Indications

2019-01-14 16:05:00 | Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2018 Financial Results

2019-01-08 08:30:00 | Caprion Biosciences Offers Mass Cytometry CRO Services to Advance Biomarker Discovery and Immune Monitoring

2018-12-23 21:49:47 | Do Hedge Funds Love Fluidigm Corporation FLDM?

2018-12-14 16:05:00 | Fluidigm Announces Closing of Public Offering of 9,372,500 Shares of Common Stock Including Full Exercise of Option to Purchase Additional Shares

2018-12-12 01:01:36 | Fluidigm Announces Pricing of Public Offering of 8,150,000 Shares of Common Stock

2018-12-11 16:01:58 | Fluidigm Announces Commencement of Public Offering of Common Stock

2018-12-05 09:15:02 | Recent Gains Cut in Half on Trade, Yield Curve Fears

2018-11-12 16:05:00 | Fluidigm to Participate in the 30th Annual Piper Jaffray Healthcare Conference

2018-11-09 16:05:00 | Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635c4

2018-11-08 08:30:00 | Fluidigm Showcases Immuno-Oncology Innovations for Translational and Clinical Research at SITC 2018

2018-11-07 16:11:23 | Fluidigm Recognized as a Company to Watch in 2019

2018-11-06 08:35:00 | Research Report Identifies Exelon, La Jolla Pharmaceutical, Kennedy-Wilson, Fluidigm, Telefonica SA, and Cognex with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2018-11-02 03:46:47 | Edited Transcript of FLDM earnings conference call or presentation 1-Nov-18 9:00pm GMT

2018-11-01 19:50:11 | Fluidigm FLDM Reports Q3 Loss, Tops Revenue Estimates

2018-11-01 18:43:37 | Fluidigm: 3Q Earnings Snapshot

2018-11-01 16:05:00 | Fluidigm Announces Third Quarter 2018 Financial Results

2018-11-01 08:30:00 | Sirona Dx Introduces Imaging Mass Cytometry Services to Advance Biomarker Discovery and Therapeutic Development

2018-10-31 08:30:00 | Laura Clague Named to Fluidigm Board of Directors

2018-10-25 08:30:00 | Foundational 10,000 Immunomes Project Uses Mass Cytometry to Establish a Reference Standard for the Human Immune System

2018-10-16 07:45:00 | Market Trends Toward New Normal in Globant S.A, EZCORP, Earthstone Energy, SPX, Fluidigm, and MAG Silver — Emerging Consolidated Expectations, Analyst Ratings

2018-10-04 08:30:00 | Fluidigm Announces Agreement with DNA Software to Offer Secondary CNV Analysis for Biomark HD

2018-10-01 16:15:00 | Fluidigm Announces Conference Call and Webcast of Third Quarter 2018 Financial Results

2018-09-27 16:05:00 | Fluidigm Introduces Single-Cell Total RNA Sequencing Applications for C1

2018-09-10 08:30:00 | Fluidigm Announces Co-Marketing Agreement with Visiopharm to Expand and Simplify Imaging Mass Cytometry Data Analysis

2018-09-07 07:30:00 | Fluidigm Partners with GenomOncology to Provide a Comprehensive Immuno-Oncology Gene Expression Solution on Biomark HD

2018-09-05 18:00:00 | Fluidigm to Participate at Upcoming Investor Events in September

2018-08-15 07:45:00 | Detailed Research: Economic Perspectives on Middlesex Water, Farmer Brothers, Fluidigm, QCR, Revlon, and Gladstone Land — What Drives Growth in Today's Competitive Landscape

2018-08-09 08:30:00 | Fluidigm to Host 2nd Annual Imaging Mass Cytometry User Group Meeting